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Abstract
Background: Individuals with a family history of depression show subtle abnormalities in the processing of social stimuli. 
This could negatively affect their interpersonal functioning and contribute to their depression risk. Repeated administration 
of the serotonin precursor tryptophan has previously been shown to increase agreeable behavior and reduce quarrelsome 
behavior in irritable people, who are also considered at risk for depression.
Methods: To examine the effects of tryptophan on social functioning in individuals with a family history of depression, 40 men 
and women with at least one first-degree relative with depression received tryptophan (1 g three times a day) and placebo for 
14 days each in a double-blind crossover design and recorded their social behavior and mood during everyday interpersonal 
encounters. Participants also provided daily ratings of their positive and negative cognitions concerning their social functioning.
Results: Tryptophan improved mood. Unexpectedly, tryptophan increased quarrelsome behavior and reduced agreeable 
behavior, specifically during interactions at home. The behavioral effects of tryptophan were not moderated by mood or by 
the interaction partner. Negative social cognitions were lower when tryptophan was given second and lower during placebo 
when placebo was given second.
Conclusion: Overall, tryptophan may not alter social behavior in individuals with a family history of depression as it does in 
irritable people. However, the behavioral effects of tryptophan at home might be seen as a way for individuals with a family 
history of depression to achieve more control. Over time, this may positively influence the way they feel and think about 
themselves in a social context.
Keywords: serotonin, social interaction, mood, major depressive disorder, dysfunctional attitudes
Introduction
Individuals with major depressive disorder (MDD) often show 
impairments in their interpersonal functioning (Hirschfeld 
et al., 2000; Hames et al., 2013). Depression has been associated 
with reduced cooperation (Hokanson et al., 1980) and elevated 
irritability and hostility (Perlis et  al., 2005). These behavioral 
patterns are thought to produce interpersonal problems that in 
turn are associated with the maintenance and severity of MDD 
(Hames et al., 2013).
Experiencing interpersonal problems may also affect the 
way MDD patients think about themselves in relation to others. 
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Depression is often accompanied by dysfunctional cognitions 
(Beck, 2008), which regularly revolve around interpersonal 
themes (Joiner, 2002). MDD patients tend to evaluate their social 
environment in a negative way (Beck, 2008) and often think they 
are regarded unfavorably by others (Youngren and Lewinsohn, 
1980). Dysfunctional cognitions are also thought to contribute 
to the course of MDD, and reducing dysfunctional cognitions 
during treatment has been suggested to contribute to treatment 
efficacy (e.g., DeRubeis et al., 1990).
Having a first-degree relative with MDD significantly 
increases the likelihood of MDD (Sullivan et al., 2000). As inter-
personal stress, rejection, and low social support are risk factors 
for MDD (Hirschfeld et al., 2000; Hames et al., 2013), it is plausi-
ble that a family history of depression (FH+) is associated with 
difficulties in social functioning. This has indeed been found 
(Watters et  al., 2013). Poor social functioning in FH+ individu-
als may be due to the existence of subtle impairments in the 
processing of emotional stimuli (Mannie et al., 2007). This can 
be a source of irritability, which is also common in FH+ individu-
als (Lauer et al., 1997). As irritability can elicit negative reactions 
in others (Moskowitz, 2010), it can cause interpersonal stress or 
rejection by others and a loss of social support. Thus, impair-
ments in the processing of emotional stimuli may negatively 
affect the social interactions of FH+ individuals and thus con-
tribute to their MDD risk.
Serotonin remains an important target in depression 
research and treatment (Albert et  al., 2012). Alterations in the 
brain serotonin system, caused by (epi)genetic factors and 
stressful experiences, are thought to lower its capacity to reg-
ulate mood, thereby predisposing individuals to MDD (Albert 
et al., 2012; Talati et al., 2013). Serotonin normally helps regu-
late mood by modulating emotional responses to environmental 
stimuli (Young, 2013; Harmer and Cowen, 2013). Environmental 
influences are often of a social nature (Kiser et al., 2012). In this 
context, it is interesting that the emotional processing impair-
ments that have been observed in FH+ individuals can be exac-
erbated both by negative mood states (Taylor and Ingram, 1999) 
and by a temporary lowering of brain serotonin levels (van der 
Veen et al., 2007; Feder et al., 2011).
Few experimental studies have assessed the role of seroto-
nin in the social functioning of MDD patients. Treatment with 
a serotonergic antidepressant has been found to reduce anger 
attacks (Fava et al., 1997) and increase extraversion (Tang et al., 
2009). In another treatment study, early reductions in subjective 
hostility predicted later antidepressant response (Farabaugh 
et al., 2010). These studies provide limited evidence that sero-
tonergic antidepressants may positively influence the social 
functioning of MDD patients and that this might contribute to 
clinical outcome.
While antidepressants have immediate synaptic effects, sev-
eral weeks of treatment are required for therapeutic effective-
ness (Frazer and Benmansour, 2002). According to Harmer et al. 
(2013), antidepressants acutely improve the processing of socio-
emotional stimuli. Over time, this remediates negative percep-
tual biases, and ultimately this contributes to reduced depressive 
symptoms. Complementary to this idea, Young et al. (2014) pro-
posed that antidepressants might work by promoting agreeable 
behavior and reducing quarrelsome behavior. Over time, these 
behavioral changes may elicit similar changes in social interac-
tion partners. The cumulative effects of more positive interactions 
may result in gradual mood improvement and may contribute to 
the clinical effectiveness of antidepressants. Overall, antidepres-
sants may improve social functioning both directly (Young et al., 
2014) and indirectly (Harmer and Cowen, 2013).
It is possible that improvements in social functioning in 
MDD patients during antidepressant treatment can occur inde-
pendently of a reduction in depressive symptoms. In line with 
this idea, antidepressant treatment has been found to improve 
aspects of social functioning in healthy volunteers. For exam-
ple, Knutson et al. (1998) observed a decrease in subjective irri-
tability and an increase in affiliative behavior during a dyadic 
puzzle task. Tse and Bond (2002) observed an increase in coop-
erative behavior during a mixed-motive game. As these stud-
ies involved computer tasks or standardized social interactions, 
single observations, and artificial settings, their relevance to 
actual social functioning may be limited.
However, other studies have used ecological momentary 
assessment (EMA) to investigate the effects of increased brain 
serotonin on social interactions (Moskowitz et al., 2001; aan het 
Rot et  al., 2006). As EMA encompasses the intensive, repeated 
assessment of people’s thoughts, feelings, and behaviors in 
everyday situations, the ecological validity of EMA data is con-
sidered high (Moskowitz and Young, 2006). Moskowitz et  al. 
(2001) found that healthy volunteers reported less quarrel-
someness when taking tryptophan, the amino acid precursor 
to serotonin, compared with when taking placebo. No signifi-
cant mood change was observed. aan het Rot et al. (2006) subse-
quently recruited healthy individuals with high trait irritability. 
Tryptophan improved mood and decreased quarrelsomeness. 
Further, tryptophan increased agreeableness, an effect that was 
independent of the observed change in mood. The study by aan 
het Rot et al. (2006) in particular provides evidence for the idea 
that increasing serotonin may promote more positive social 
interactions directly (cf. Young et al., 2014 discussed above).
Similar to high trait irritable individuals (Conner et al., 2003), 
FH+ individuals constitute a population at high risk for MDD 
(Sullivan et  al., 2000). Studies in FH+ individuals may inform 
about the role of serotonin in social functioning in MDD even 
more than studies conducted with high trait irritable individu-
als (cf. aan het Rot et al., 2006). Since many FH+ individuals have 
never used psychotropic medications, the effects of tryptophan 
can be studied without needing to take depressive symptoms 
and antidepressant use into account.
The present EMA study assessed the effects of tryptophan 
on the social interactions of FH+ individuals. As we aimed to 
extend previous findings, we hypothesized that tryptophan 
would decrease quarrelsomeness, increase agreeableness, and 
improve mood. We also aimed to assess the effects of trypto-
phan on social cognitions. Specifically, we hypothesized that 
when taking tryptophan individuals would report more positive 
and fewer negative thoughts about themselves in relation to 
others. Social cognitions were assessed at the end of each day of 
EMA, so we could determine whether the effects of tryptophan 




The study was approved by the Medical Ethics Committee of the 
University Medical Centre Groningen and executed in accord-
ance with the Declaration of Helsinki. All participants signed an 
informed consent form after the procedures of the study had 
been explained to them in writing and verbally. They received 
100 euro for their participation.
Men and women could participate if they had at least one 
first-degree family member with MDD and met the following 
Downloaded from https://academic.oup.com/ijnp/article-abstract/18/8/pyv012/2910026
by University of Groningen user
on 29 November 2017
Hogenelst et al. | 3
inclusion criteria: age 18 to 65 years, no current or past DSM-IV 
mood disorder including MDD, no other current DSM-IV Axis-1 
disorder, no current major medical illness, no current use of 
psychotropic medications, and no contraindication for the use 
of tryptophan. Participants were screened using the Structured 
Clinical Interview for DSM-IV Axis I disorders (First et al., 2002) 
and asked about their psychiatric family history using the 
method described by Andreasen et al. (1977).
Full details of the screening phase can be found in the sup-
plementary information. Briefly, 42 participants started the study. 
One participant dropped out after 5  days and one participant 
admitted after the study to nonadherence to the EMA instructions. 
The results are described for 40 participants (13 men, 27 women).
Treatment
In a double-blind crossover design, all participants took two 500-
mg l-tryptophan (Cell Care, Putten, The Netherlands) or identi-
cal placebo capsules 3 times a day for 14 days. Treatment order 
was counterbalanced within gender. We implemented a 7-day 
inter-treatment interval. The 3-g daily dose of tryptophan was 
identical to the daily dose used in previous studies (Moskowitz 
et al., 2001; aan het Rot et al., 2006).
EMA
Participants used EMA to record their social interactions 
throughout the 2 treatment periods. Standardized forms asked 
participants about the broad social context of each interaction 
and how they behaved and felt. Participants were instructed to 
record alcohol use in the 3 hours before or during the interaction 
and to not complete any forms after illicit drug use.
Measurement of Behavior
We used a Dutch translation of the Social Behavior Inventory (SBI) 
(Moskowitz, 1994), previously found to differ minimally in the 
interpretation of the 46 behavioral items (aan het Rot et al., 2013). 
These items are used to assess agreeableness (e.g., “I exchanged 
pleasantries”), quarrelsomeness (e.g., “I confronted the other 
about something I  did not like”), dominance (e.g., “I assigned 
someone to a task”), or submissiveness (e.g. “I gave in”). One item 
assesses both dominance and quarrelsomeness (“I criticized the 
other”) and one item assesses both agreeableness and submis-
siveness (“I went along with the other”). The original SBI has been 
shown to provide valid and reliable scores of each dimension of 
social behavior (Moskowitz, 1994; Moskowitz and Sadikaj, 2012).
Participants were instructed to mark all behaviors they engaged 
in during a social interaction. The 46 SBI items were divided over 
4 forms, rotated on a daily basis to prevent participants from 
marking the same behaviors for every interaction. On each form, 
each dimension of behavior was represented by 3 items. Ipsatized 
behavior scores were calculated using the method previously 
described by Moskowitz et al. (2001) and aan het Rot et al. (2006). 
These ipsatized scores reflect the extent to which behaviors per-
taining to a specific dimension are checked relative to a partici-
pant’s overall rate of behavior checking. As people tend to check 
quarrelsome and submissive behaviors less often than agreeable 
and dominant behaviors, the ipsatized scores for quarrelsome and 
submissive behaviors tend to be low, and often negative.
Mood Measurement
A list of affect adjectives was used as a proxy for mood state 
(Diener and Emmons, 1984). On each form these were rated on a 
scale from 0 (not at all) to 6 (extremely). Event-level means were 
calculated for positive affect (PA) (e.g., happy, pleased, joyful) 
and negative affect (NA) (e.g., worried/anxious, angry/hostile, 
depressed) separately.
Measurement of Daily Social Cognitions
At the end of each day, participants were asked to indicate on a 
scale from 0 (not at all) to 6 (all the time) to what extent they had 
certain negative thoughts (e.g., “No one understands me”) and 
certain positive thoughts (e.g., “I have a good way with others”). 
The list of social cognitions contained 12 items (see supplemen-
tal Information for more information).
A factor analysis of the data obtained in the placebo phase 
indicated a 3-factor structure with all 6 positive cognitions load-
ing on 1 factor, 5 negative cognitions loading on the second fac-
tor, and 1 negative cognition loading on a third factor (“I am a 
social failure”). Internal consistency measured by calculating 
Cronbach’s alpha was excellent for the items representing posi-
tive cognitions (α  =  0.95) and acceptable for the negative cog-
nitions loading on the second factor (α = 0.60). Thus, day-level 
means were calculated for the 6 positive cognitions and for 5 of 
the 6 negative cognitions.
Procedure
The day before the first EMA day, participants were instructed 
extensively about the method. They also completed the Quick 
Inventory of Depressive Symptomatology (QIDS-SR) (Rush et al., 
2003) and the Revised Leiden Index of Depression Severity 
(LEIDS-R) (Van der Does, 2002). For the 28 assessment days, 
participants received 2 packages, each with 14 preaddressed 
stamped envelopes. Each envelope contained 10 social interac-
tion forms and the tryptophan or placebo capsules for that day. 
We instructed participants to complete the forms immediately 
after significant interactions, defined as at least 5 minutes of 
conversation with 1 or more persons. Each day, participants also 
recorded time of capsule ingestion, and women recorded if they 
were menstruating. After each treatment phase, participants 
recompleted the QIDS-SR and the LEIDS-R and were asked about 
side effects experienced in the past 2 weeks.
Data Analysis
We excluded social interactions that took place within 3 hours 
of alcohol ingestion (5.5% of 6141 events). Outcome variables 
were quarrelsome, agreeable, dominant, and submissive behav-
ior, PA, and NA, positive social cognitions, and negative social 
cognitions. We considered the within-subjects factor treatment 
(tryptophan vs placebo), the between-subjects factors order 
(tryptophan first, placebo first), and their interaction as possible 
predictors. We did not expect any treatment by gender effects, 
but to control for the possible effects of gender, we included this 
factor as a covariate.
To test our hypotheses we used mixed linear modeling with 
maximum likelihood estimation in R v3.0.2 (www.r-project.org). 
Statistical significance was set at 0.05. Tukey-Kramer corrections 
for multiple comparisons were used for analysis of significant 
interaction effects. Treatment effects are reported using esti-
mated least squares means and SEM. Effect sizes were estimated 
using Cohen’s d. These values represent event-level effects for 
behaviors and mood and day-level effects for cognitions.
Posthoc analyses were conducted to determine the con-
text in which tryptophan influenced social interactions. Based 
on previous research (Barker and Lemle, 1987; Moskowitz and 
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Sadikaj, 2012), we created the following categorical contextual 
variables: location (home, elsewhere), partner sex (male, female), 
time of interaction (morning, afternoon, evening), and week 
of treatment phase (week 1, week 2). For the contextual vari-
able relationship status, we created 2 categories: close (friend, 
romantic partner, or family member) and not close (people at 
work, acquaintance, or other).
In addition, covariate analyses were performed to exam-
ine the extent to which tryptophan-induced changes in social 
behaviors and cognitions co-occurred with changes in mood. To 
this end, PA or NA were added as event-level covariates to the 
models for behavior, and mean PA or NA scores were added as 
day-level covariates to the models for cognitions.
Results
There were no significant gender differences in age, QIDS-SR 
scores, and LEIDS-R scores (Table 1). After completing the study, 
31% of the men and 48% of the women were correct in guessing 
when they were taking tryptophan. These percentages were not 
significantly different from chance (Table 1).
Internal Consistency and Stability across Days of the 
Behavior Scales
Using the placebo data and otherwise analogous to Moskowitz 
(1994), we examined inter-item reliability for each of the behav-
ior scales by calculating the Cronbach coefficient α for the 12 
items of each scale. Internal consistency was high for all 4 scales 
(0.75 < α < 0.89).
For stability across days, we constructed scale scores for each 
placebo day by first calculating the mean of the ipsatized items 
for each scale for each day and then the Cronbach coefficient α 
for each scale. Across days, the stability was high for agreeable-
ness (α = 0.79) and quarrelsomeness (α = 0.83) and moderate for 
dominance (α = 0.68) and submissiveness (α = 0.57). These values 
are very similar to the values reported by Moskowitz (1994).
Planned Analyses at Event Level
Table 2 shows the effects of treatment, order, and the treatment 
by order interaction on behavior and mood (Table 2).
Effects of Treatment on Social Behaviors
For quarrelsomeness, the main effects of treatment and order 
were significant. Quarrelsomeness was higher during trypto-
phan (M  =  -14.0, SEM  =  0.90) than during placebo (M  =  -15.12, 
SEM = 0.90, d = 0.07). Quarrelsomeness was lower in the group 
that received tryptophan first (M = -16.2, SEM = 1.27) than in the 
group that received placebo first (M = -12.96, SEM = 1.12, d = 0.65).
For agreeableness, the effects of treatment and order and the 
treatment by order interaction were not significant. However, agree-
able behavior tended to be lower during tryptophan (M  =  12.99, 
SEM = 1.15) than during placebo (M = 13.98, SEM = 1.15, d = 0.05).
For dominant behavior, there was no significant effect of 
treatment. The main effect of order was significant. Dominant 
behavior was higher in the group that received tryptophan first 
(M = 9.28, SEM = 1.28) than in the group that received placebo 
first (M = 5.85, SEM = 1.13, d = 0.68). The treatment by order inter-
action was not significant.
For submissive behavior, there were no significant effects of 
treatment, order, and their interaction.
Effects of Tryptophan on Mood
For PA, there were significant effects of treatment and of the 
treatment by order interaction. PA was higher during tryptophan 
(M = 3.36, SEM = 0.18) than during placebo (M = 3.21, SEM = 0.18, 
t5570 = -4.10, P < .001, d = 0.11) in participants who received tryp-
tophan second, but not in participants who received trypto-
phan first (placebo: 3.14 [SEM 0.20]; tryptophan: 3.16 [SEM 0.20], 
t5569 = -0.56, P = .94, d = 0.02).
For NA, there was a significant effect of treatment and a 
trend for a treatment by order effect. NA was significantly lower 
during tryptophan (M  =  0.31, SEM = 0.07) than during placebo 
(M = 0.40, SEM = 0.07, t5556 = 4.58, P < .001, d = 0.12) in participants 
who received tryptophan second, but not in participants who 
received tryptophan first (placebo: 0.30 [SEM 0.08]; tryptophan: 
0.26 [SEM 0.08], t5556 = 1.66, P = .34, d = 0.04).
Posthoc Analyses at Event Level
We conducted additional analyses to determine whether the 
(unexpected) increase in quarrelsomeness reported during the 
tryptophan phase was moderated by context. Quarrelsomeness 
was the dependent variable, and we entered treatment, order, one 
of the contextual variables (see Data analysis section), and the 2- 
and 3-way interactions as predictors. Again, participant gender was 
added as a covariate. Since agreeableness tended to decrease in the 
tryptophan phase, we conducted similar analyses for agreeableness.
For both quarrelsomeness and agreeableness, only location 
(coded as home vs elsewhere) was found to moderate the effects 
of tryptophan. The percentage of interactions at home was 46.4 
% in the placebo phase and 47.4% in the tryptophan phase. 
Interactions at home primarily involved a romantic partner 
(37%), followed by a friend (20 %), a parent (15 %), or a child (12 %), 
with no meaningful differences between the 2 treatment phases.
The treatment by location interaction was significant for 
quarrelsome behavior (F1,5714  =  4.05, P  =  .04). Quarrelsomeness Table  1. Characteristics of Study Participants Expressed in mean 
(SD) Values
Characteristic Men (n = 13) Women (n = 27)
Age, y 30.4 (13.6) 32.5 (15.2)
QIDS-SR16 score before study 2.8 (1.9) 2.0 (2.0)
QIDS SR16 score after study 2.8 (1.9) 2.3 (1.9)
LEIDS-R score before study 27.4 (13.1) 28.9 (9.3)
LEIDS-R score after study 27.4 (13.8) 27.2 (15.8)
Proband is parent 61 % 48 %
Proband is sibling 31 % 30 %
Proband is child 8 % 22 %
Abbreviations: LEIDS-R, Leiden Index of Depression Severity-Revised; QIDS-
SR16, Quick Inventory of Depressive Symptoms–Self-Report 16 items.
Table 2. F-Values for the Effects of Treatment, Order, and Their Inter-
action on Behavior and Mood
Treatment Order Treatment × Order
Quarrelsome behaviors 6.11* 4.25* 1.91
Agreeable behaviors 3.04† 0.13 0.95
Dominant behaviors 0.81 4.68* 2.17
Submissive behaviors 0.74 0.40 2.43
Positive affect 10.08** 0.30 5.51*
Negative affect 18.59*** 0.57 3.41†
*P < .05, **P < .01, ***P <.001, †P < .1.
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was higher during tryptophan than during placebo when par-
ticipants were at home (t5701 = -3.00, P =  .014, d = 0.08), but not 
elsewhere (t5710 = -0.22, P = .99, d < 0.01) (Figure 1a).
Similarly, there was a significant treatment by location 
interaction for agreeable behavior (F1,5714  =  11.55, P < .001). 
Agreeableness was lower during tryptophan than during pla-
cebo when participants were at home (t5702  =  3.64, P  =  .002, 
d = 0.1) but not elsewhere (t5710 = -1.12, P = .68, d = 0.03) (Figure 1b).
For dominant and submissive behavior and for PA and NA, 
there were no significant interaction effects between treatment 
and location (all Fs < 2.25, P > .13), nor between treatment and 
any other contextual variable.
Covariate Analyses at Event Level
Quarrelsomeness was negatively associated with PA 
(F1,4369  =  107.4, P < .001). Similarly, quarrelsomeness was posi-
tively associated with NA (F1,5358 = 90.4, P < .001). Nevertheless, 
the effect of treatment on quarrelsomeness at home remained 
significant after we controlled for PA or NA (all ts > -3.0, P < .02).
Agreeableness was positively associated with PA 
(F1,4439 = 226.6, P < .001). Similarly, agreeableness was negatively 
associated with NA (F1,5355 = 69.2, P < .001) were associated with 
higher levels of agreeableness. Nevertheless, the effect of treat-
ment on agreeableness at home remained significant after we 
controlled for PA or NA (all ts > 3.7, P < .002).
Planned Analyses at Day Level
For negative social cognitions, there was a significant treatment 
by order effect (F1,1035 = 19.4, P < .001). Negative social cognitions 
where lower in the tryptophan phase when tryptophan was given 
second (t1039 = 3.26, P = .006, d = 0.20) and lower under placebo when 
placebo was given second (t1039 = -3.0, P = .01, d = 0.19) (Figure 2).
For positive social cognitions, there were no significant effects of 
treatment or interactions involving treatment (all Fs < 2.25, P > .14).
Covariate Analyses at Day Level
The effect of the treatment by order interaction on negative 
cognitions remained significant when we controlled for PA, NA, 
for quarrelsomeness or agreeableness in general, or for quar-
relsomeness or agreeableness at home (all Fs > 12.0, P < .001).
Discussion
We studied the effects of tryptophan on the interpersonal 
encounters and social cognitions of individuals at risk for 
depression. Tryptophan improved mood and, specifically dur-
ing interactions at home, increased quarrelsome behavior and 
decreased agreeable behavior. Further, negative social cogni-
tions were lower during tryptophan when tryptophan was 
given second and lower during placebo when it was given 
second.
The observed behavioral effects were opposite to the hypoth-
esized effects. Tryptophan was previously found to increase 
agreeableness and decrease quarrelsomeness in individuals 
with high trait quarrelsomeness (aan het Rot et al., 2006), another 
population considered at risk for depression. Comparatively, 
however, levels of quarrelsomeness during tryptophan treat-
ment were significantly lower in our study than levels of quar-
relsomeness during placebo treatment in the previous study 
(but see aan het Rot et al., 2006). Thus, the level to which tryp-
tophan increased quarrelsome behavior in the FH+ individuals 
was not as high as the baseline level of quarrelsome behavior in 
the irritable people. This suggests that FH+ individuals may not 
be as comparable with irritable people as we thought in terms of 
their social functioning, even though both groups are at elevated 
risk for MDD.
Given the unexpected behavioral findings, we examined 
contextual moderators of the effects of tryptophan on quar-
relsomeness and agreeableness. We found that the increase 
in quarrelsomeness and decrease in agreeableness observed 
during tryptophan treatment only occurred during interac-
tions at home. As the types of interaction partner at home (e.g., 
romantic partner) were similar for both treatment phases, our 
behavioral findings cannot be attributed to a phase difference 
in interaction partners. Moreover, the effects of tryptophan on 
quarrelsomeness and agreeableness at home were independent 
of concurrent levels of dominant behavior, submissive behavior, 
PA, and NA.
As quarrelsomeness often occurs in response to contextual 
cues, it can be considered a mild form of reactive aggression 
(Moskowitz, 2010). Laboratory models of aggression in rodents 
suggest that normal adaptive reactive aggression may be aimed 
at increasing territorial control and social status and that this 
type of aggression is positively associated with activity of brain 
serotonin neurons (de Boer et al., 2009). Therefore, the observed 
tryptophan-induced increase in quarrelsomeness may have 
helped the participating FH+ individuals to increase control over 
their social environment. The fact that behavior changed only at 
home is consistent with a tendency to be less polite and more 
Figure 1. Ipsatized mean scores for quarrelsomeness and agreeableness in interactions at home and away from home during tryptophan and placebo treatment 
(values are estimated least squares means and SEs).
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critical towards others in familiar situations than in unfamiliar 
situations (Barker and Lemle, 1987).
Tryptophan supplementation improved mood. This is in line 
with the previous study by aan het Rot et  al. (2006) and with 
research showing that prolonged increases in brain seroto-
nin induced by antidepressants can improve mood in healthy 
individuals (Serretti et al., 2010). One other study assessed the 
effects of prolonged increases in serotonin in FH+ individuals 
and found no effect on mood (Knorr et al., 2012). However, mood 
was measured using the Hamilton Depression Rating Scale, 
which assesses recent depressive symptoms and may not be 
sensitive to day-to-day changes in mood. In line with this, we 
found no effect of tryptophan on depressive symptoms meas-
ured using the QIDS-SR.
Tryptophan increased both quarrelsome behavior and 
mood. This may seem in contradiction to the behavioral find-
ings. Indeed, people usually experience more NA when they 
are more quarrelsome (Moskowitz and Coté, 1995). Yet the 
effect of tryptophan on quarrelsomeness at home did not 
change when we controlled for PA or NA. Thus, tryptophan 
increased quarrelsome behaviors in different interactions at 
home than in the interactions at home in which it improved 
mood. A  recent EMA study in people with mild to moderate 
seasonality reported an increase in quarrelsomeness along 
with an increase in mood during a bright light intervention 
(Hsu et  al., 2014). The authors suggested that an increase in 
mood in the majority of social interactions together with a 
small but significant increase in quarrelsomeness in some 
interactions may be an explanation for their findings. As 
bright light is thought to increase brain serotonin (aan het Rot 
et al., 2008), the results of the study by Hsu et al. (2014) are in 
line with the present results.
To determine the degree to which the effects of tryptophan 
might extend beyond the level of individual social interactions, 
at the end of each day we assessed how people thought of them-
selves in relation to others. When tryptophan was given second, 
it reduced negative social cognitions, which was in line with our 
hypothesis. Previous studies in FH+ individuals have reported a 
negative bias in emotional processing (van der Veen et al., 2007; 
Feder et al., 2011). Further, research shows that antidepressant 
treatment can reduce negative biases in emotion processing 
(Harmer and Cowen, 2013). Thus, it may be that participants 
who received tryptophan second initially evaluated their social 
functioning in a negatively biased way and that tryptophan 
reduced this bias.
 However, when tryptophan was given first, negative social 
cognitions were subsequently decreased in the placebo phase. 
This is not in line with the idea that tryptophan reduces nega-
tive cognitive biases. One alternative explanation for the find-
ings is that the level of negative social cognitions decreased over 
time in both treatment order groups. Nevertheless, the possible 
effects of tryptophan on negative social cognitions need to be 
interpreted with caution.
Strengths and Limitations
To our knowledge, this is the first study to assess the effects 
of increased brain serotonin on daily social functioning in FH+ 
individuals. As we studied the social interactions that occurred 
in real life, the study has high ecological validity.
We used a Dutch translation of the SBI. The original English 
version has been extensively validated (Moskowitz, 1994; 
Moskowitz and Sadikaj, 2012), and we previously obtained evi-
dence for the construct validity of the Dutch translation (aan het 
Rot et al., 2013). Further, the internal consistency and reliabil-
ity across days of the 4 Dutch behavior scales were comparable 
with those of the English scales, suggesting that the Dutch SBI, 
like the English SBI, had good psychometric properties.
In spite of these strengths, our study may have been under-
powered to examine statistical interaction effects in detail 
posthoc. Further, the unequal numbers of men and women 
precluded a comparison of treatment effects between genders. 
Furthermore, like previous research (Mannie et  al., 2007), we 
included children and siblings of individuals with MDD. Unlike 
previous studies, however, we also allowed parents to par-
ticipate (18% of our sample). FH+ parents may have a different 
MDD risk profile than FH+ siblings and children. In fact, older 
FH+ individuals in general may be more likely to be resilient to 
depression than younger individuals. Nevertheless, the results 
were not moderated by whether participants had a child, sibling, 
or parent with MDD (data not shown).
Finally, though the family history method we used pro-
vides insight in inter-individual variability in familial MDD load 
(Andreasen et al., 1977), it does not yield MDD diagnoses in relatives. 
FH+ individuals with multiple family members diagnosed with MDD 
may respond differently to tryptophan than FH+ individuals with a 
single affected family member. We were unable to formally test this.
Future Studies
Our results suggest it may be relevant to examine the effects of 
increasing brain serotonin on the home interactions of FH+ indi-
viduals in more detail. Future studies may focus on the inter-
actions of FH+ individuals with their spouse or with depressed 
relatives living at home. Interpersonal deficits of depressed indi-
viduals tend to be more pronounced in the context of significant 
relationships (Joiner, 2002; Rehman et al., 2010). This may also be 
true for FH+ individuals.
As mentioned in the Introduction, Young and colleagues 
(2014) recently proposed that serotonergic antidepressants in 
depressed individuals might work by acutely promoting more 
positive social behavior and that this will gradually result in 
mood improvement. This idea was largely based on a previous 
study in individuals with high trait quarrelsomeness, who are 
also thought to be at risk for MDD (Conner et al., 2003). In this 
population, tryptophan reduced quarrelsomeness and increased 
agreeableness (aan het Rot et al., 2006). As we were unable to 
Figure 2. Negative social cognitions during tryptophan and placebo treatment 
separated by order (values are estimated least squares means and SEs).
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extend these effects of tryptophan to FH+ individuals in the 
present study, there are implications for the model proposed 
by Young et  al. (2014). Our results suggest that serotonergic 
antidepressants might actually increase quarrelsomeness and 
decrease agreeableness in some MDD patients when they start 
treatment. While their mood might improve, the effects of social 
interaction at home would potentially be less desirable and even 
negatively affect patients’ interpersonal relationships with pro-
longed treatment. This could be examined in future studies.
In light of the above, a final suggestion for the future would 
be to conduct a meta-analysis on the effects of tryptophan on 
everyday interpersonal encounters. This might help elucidate 
whether, across the 3 EMA studies conducted to date, there 
exists indeed a group of individuals whose mood improves when 
they behave in a more agreeable and less quarrelsome way and 
a group of individuals whose mood improves when they behave 
in a less agreeable and more quarrelsome way.
Conclusion
The present study does not provide straightforward evidence 
that increasing brain serotonin positively influences the inter-
personal encounters of individuals with a family history of 
depression (FH+). However, by increasing quarrelsome behavior 
and decreasing agreeable behavior at home, tryptophan may 
provide a way for FH+ individuals to achieve more control. The 
observed changes in mood and social cognitions are not neces-
sarily in disagreement with this idea.
Acknowledgments
This work was supported by a Veni grant awarded to Dr. aan 
het Rot by the Netherlands Organization for Scientific Research 
(NWO). The NWO had no further role in study design; in the col-
lection, analysis, and interpretation of data; in the writing of 
the report; or in the decision to submit the paper for publica-
tion. We are very grateful to the participants of our study. We 
thank Annika Luckmann, Lisanne Wichgers, Pia Sailer, Minita 
Franzen, and Sofie Møller Sørensen for their research assistance. 
The study was presented in poster format at the Collegium 
Internationale Neuro-Psychopharmacologicum 29th Congress: 




aan het Rot M, Moskowitz DS, Pinard G, Young SN (2006) Social 
behaviour and mood in everyday life: the effects of tryp-
tophan in quarrelsome individuals. J Psychiatry Neurosci 
31:253–262.
aan het Rot M, Benkelfat C, Boivin DB, Young SN (2008) Bright 
light exposure during acute tryptophan depletion prevents a 
lowering of mood in mildly seasonal women. Eur Neuropsy-
chopharmacol 18:14–23.
aan het Rot M, Hogenelst K, Moskowitz DS (2013) Comparability 
of the social behavior inventory in English and Dutch. J Pers 
Assess 95:500–505.
Albert PR, Benkelfat C, Descarries L (2012) The neurobiology of 
depression--revisiting the serotonin hypothesis. I.  Cellular 
and molecular mechanisms. Philos Trans R Soc Lond B Biol 
Sci 367:2378–2381.
Andreasen NC, Endicott J, Spitzer RL, Winokur G (1977) The fam-
ily history method using diagnostic criteria. reliability and 
validity. Arch Gen Psychiatry 34:1229–1235.
Barker C, Lemle R (1987) Informal helping in partner and stran-
ger dyads. Journal of Marriage and Family 49:541–547.
Beck AT (2008) The evolution of the cognitive model of depres-
sion and its neurobiological correlates. Am J Psychiatry 
165:969–977.
Conner KR, Duberstein PR, Conwell Y, Caine ED (2003) Reactive 
aggression and suicide: theory and evidence. Aggress Violent 
Behav 8:413–432.
de Boer SF, Caramaschi D, Natarajan D, Koolhaas JM (2009) The 
vicious cycle towards violence: focus on the negative feed-
back mechanisms of brain serotonin neurotransmission. 
Front Behav Neurosci 3:52.
DeRubeis RJ, Evans MD, Hollon SD, Garvey MJ, Grove WM, Tuason 
VB (1990) How does cognitive therapy work? Cognitive change 
and symptom change in cognitive therapy and pharmaco-
therapy for depression. J Consult Clin Psychol 58:862–869.
Diener E, Emmons RA (1984) The independence of positive and 
negative affect. J Pers Soc Psychol 47:1105–1117.
Farabaugh A, Sonawalla S, Johnson DP, Witte J, Papakostas GI, 
Goodness T, Clain A, Baer L, Mischoulon D, Fava M, Harley R 
(2010) Early improvements in anxiety, depression, and anger/
hostility symptoms and response to antidepressant treat-
ment. Ann Clin Psychiatry 22:166–171.
Fava M, Nierenberg AA, Quitkin FM, Zisook S, Pearlstein T, Stone 
A, Rosenbaum JF (1997) A preliminary study on the efficacy 
of sertraline and imipramine on anger attacks in atypical 
depression and dysthymia. Psychopharmacol Bull 33:101–103.
Feder A, Skipper J, Blair JR, Buchholz K, Mathew SJ, Schwarz M, 
Doucette JT, Alonso A, Collins KA, Neumeister A, Charney DS 
(2011) Tryptophan depletion and emotional processing in 
healthy volunteers at high risk for depression. Biol Psychiatry 
69:804–807.
First MB, Spitzer RL, Gibbon M, and Williams JBW (2002) Struc-
tured clinical interview for DSM-IV-TR axis I  disorders, 
research version, patient edition. (SCID-I/P). New York: Biom-
etrics Research, New York State Psychiatric Institute.
Frazer A, Benmansour S (2002) Delayed pharmacological effects 
of antidepressants. Mol Psychiatry 7:S23–8.
Hames JL, Hagan CR, Joiner TE (2013) Interpersonal processes in 
depression. Annu Rev Clin Psychol 9:355–377.
Harmer CJ, Cowen PJ (2013) ‘It’s the way that you look at 
it’--a cognitive neuropsychological account of SSRI 
action in depression. Philos Trans R Soc Lond B Biol Sci 
368:20120407.
Hirschfeld RM, Montgomery SA, Keller MB, Kasper S, Schatzberg 
AF, Moller HJ, Healy D, Baldwin D, Humble M, Versiani M, Mon-
tenegro R, Bourgeois M (2000) Social functioning in depres-
sion: a review. J Clin Psychiatry 61:268–275.
Hokanson JE, Sacco WP, Blumberg SR, Landrum GC (1980) Inter-
personal behavior of depressive individuals in a mixed-
motive game. J Abnorm Psychol 89:320–332.
Hsu ZY, Moskowitz DS, Young SN (2014) The influence of light 
administration on interpersonal behavior and affect in peo-
ple with mild to moderate seasonality. Prog Neuropsychop-
harmacol Biol Psychiatry 48:92–101.
Joiner TEJ (2002) Depression in its interpersonal context. (Got-
lib IH, Hammen CL, eds), pp. 295–313. New York, NY: Guilford 
Press.
Kiser D, Steemers B, Branchi I, Homberg JR (2012) The reciprocal 
interaction between serotonin and social behaviour. Neurosci 
Biobehav Rev 36:786–798.
Downloaded from https://academic.oup.com/ijnp/article-abstract/18/8/pyv012/2910026
by University of Groningen user
on 29 November 2017
8 | International Journal of Neuropsychopharmacology, 2015
Knorr U, Vinberg M, Mortensen EL, Winkel P, Gluud C, Wetterslev 
J, Gether U, Kessing LV (2012) Effect of chronic escitalopram 
versus placebo on personality traits in healthy first-degree 
relatives of patients with depression: a randomized trial. 
PLoS One 7:e31980.
Knutson B, Wolkowitz OM, Cole SW, Chan T, Moore EA, Johnson 
RC, Terpstra J, Turner RA, Reus VI (1998) Selective alteration of 
personality and social behavior by serotonergic intervention. 
Am J Psychiatry 155:373–379.
Lauer CJ, Bronisch T, Kainz M, Schreiber W, Holsboer F, Krieg JC 
(1997) Pre-morbid psychometric profile of subjects at high 
familial risk for affective disorder. Psychol Med 27:355–362.
Mannie ZN, Bristow GC, Harmer CJ, Cowen PJ (2007) Impaired 
emotional categorisation in young people at increased famil-
ial risk of depression. Neuropsychologia 45:2975–2980.
Moskowitz DS (1994) Cross-situational generality and the inter-
personal circumplex. J Pers Soc Psych 66:921–933.
Moskowitz DS (2010) Quarrelsomeness in daily life. J Pers 78:39–
66.
Moskowitz DS, Coté S (1995) Do interpersonal traits predict 
affect? A  comparison of three models. J Pers Soc Psychol 
69:915–924.
Moskowitz DS, Pinard G, Zuroff DC, Annable L, Young SN (2001) 
The effect of tryptophan on social interaction in everyday 
life: a placebo-controlled study. Neuropsychopharmacology 
25:277–289.
Moskowitz DS, Young SN (2006) Ecological momentary assess-
ment: what is it and why is it a measure of the future in clini-
cal psychopharmacology. J Psych Neurosci 31:13–20.
Moskowitz DS, Sadikaj G (2012) Event-contingent recording. 
(Mehl MR, Conner TS, eds), pp. 160–175. New York, NY: Guil-
ford Press.
Perlis RH, Fraguas R, Fava M, Trivedi MH, Luther JF, Wisniewski 
SR, Rush AJ (2005) Prevalence and clinical correlates of irrita-
bility in major depressive disorder: a preliminary report from 
the sequenced treatment alternatives to relieve depression 
study. J Clin Psychiatry 66:159–66.
Rehman US, Ginting J, Karimiha G, Goodnight JA (2010) Revisiting 
the relationship between depressive symptoms and marital 
communication using an experimental paradigm: the mod-
erating effect of acute sad mood. Behav Res Ther 48:97–105.
Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein 
DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase 
ME, Kocsis JH, Keller MB (2003) The 16-item quick inventory 
of depressive symptomatology (QIDS), clinician rating (QIDS-
C), and self-report (QIDS-SR): a psychometric evaluation in 
patients with chronic major depression. Biol Psychiatry 
54:573–583.
Serretti A, Calati R, Goracci A, Di Simplicio M, Castrogiovanni P, 
De Ronchi D (2010) Antidepressants in healthy subjects: what 
are the psychotropic/psychological effects? Eur Neuropsy-
chopharmacol 20:433–453.
Sullivan PF, Neale MC, Kendler KS (2000) Genetic epidemiology of 
major depression: review and meta-analysis. Am J Psychiatry 
157:1552–1562.
Talati A, Weissman MM, Hamilton SP (2013) Using the high-risk 
family design to identify biomarkers for major depression. 
Philos Trans R Soc Lond B Biol Sci 368:20120129.
Tang TZ, DeRubeis RJ, Hollon SD, Amsterdam J, Shelton R, Scha-
let B (2009) Personality change during depression treatment: 
a placebo-controlled trial. Arch Gen Psychiatry 66:1322–1330.
Taylor L, Ingram RE (1999) Cognitive reactivity and depressotypic 
information processing in children of depressed mothers. J 
Abnorm Psychol 108:202–210.
Tse WS, Bond AJ (2002) Serotonergic intervention affects both 
social dominance and affiliative behaviour. Psychopharma-
cology (Berl) 161:324–330.
Van der Does W (2002) Cognitive reactivity to sad mood: struc-
ture and validity of a new measure. Behav Res Ther 40:105–
120.
van der Veen FM, Evers EA, Deutz NE, Schmitt JA (2007) Effects of 
acute tryptophan depletion on mood and facial emotion per-
ception related brain activation and performance in healthy 
women with and without a family history of depression. 
Neuropsychopharmacology 32:216–224.
Watters AJ, Gotlib IH, Harris AW, Boyce PM, Williams LM (2013) 
Using multiple methods to characterize the phenotype of 
individuals with a family history of major depressive disor-
der. J Affect Disord 150:474–480.
Young SN (2013) The effect of raising and lowering tryptophan 
levels on human mood and social behaviour. Philos Trans R 
Soc Lond B Biol Sci 68:20110375.
Young SN, Moskowitz DS, aan het Rot M (2014) Possible role of 
more positive social behaviour in the clinical effect of antide-
pressant drugs. J Psychiatry Neurosci 39:60–65.
Youngren MA, Lewinsohn PM (1980) The functional relation 
between depression and problematic interpersonal behavior. 
J Abnorm Psychol 89:333–341.
Downloaded from https://academic.oup.com/ijnp/article-abstract/18/8/pyv012/2910026
by University of Groningen user
on 29 November 2017
